References
- Mitchell BS, Kelley WN. Purinogenic immunodeficiency diseases: clinical features and molecular mechanisms. Ann Intern Med 1980;92:826–831.
- Johnston JB, Begleiter A, Pugh L, Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Res 1986;46:2179–2184.
- Begleiter A, Glazer RI, Israels LG, Induction of DNA strand breaks in chronic lymphocytic leukemia following treatment with 2′-deoxycoformycin in vivo and in vitro. Cancer Res 1987;47:2498–2503.
- Pastor-Anglada M, Molina-Arcas M, Casado FJ, Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 2004;18:385–393.
- Seto S, Carrera CJ, Kubota M, Wasson B, Carson DA. Mechanism of dAdo and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985;75:377–382.
- Begleiter A, Pugh L, Israels LG, Johnston JB. Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2′-deoxycoformcyin and dAdo in vitro. Cancer Res 1988;48:3981–3986.
- Genini D, Adachi S, Chao Q, Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537–3543.
- Pettitt AR, Sherrington PD, Cawley JC. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Cancer Res 2000;60:4187–4193.